Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report. Here, ERBB2 is linked to digestive system mixed adenoneuroendocrine carcinoma.